Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
22.17
+0.31 (1.42%)
At close: Dec 9, 2025, 4:00 PM EST
22.16
-0.01 (-0.05%)
After-hours: Dec 9, 2025, 5:59 PM EST
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
The 26 analysts that cover Sarepta Therapeutics stock have a consensus rating of "Hold" and an average price target of $26.23, which forecasts a 18.31% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $81.
Price Target: $26.23 (+18.31%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Sarepta Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 7 | 7 | 8 | 7 | 7 | 7 |
| Hold | 14 | 14 | 14 | 14 | 14 | 14 |
| Sell | 2 | 2 | 2 | 2 | 2 | 2 |
| Strong Sell | 3 | 4 | 4 | 4 | 4 | 4 |
| Total | 29 | 30 | 31 | 30 | 30 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Initiates $32 | Buy | Initiates | $32 | +44.34% | Dec 9, 2025 |
| Barclays | Barclays | Hold Maintains $22 → $20 | Hold | Maintains | $22 → $20 | -9.79% | Nov 5, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $50 → $45 | Buy | Maintains | $50 → $45 | +102.98% | Nov 5, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $22 → $19 | Strong Buy | Maintains | $22 → $19 | -14.30% | Nov 5, 2025 |
| Mizuho | Mizuho | Hold → Buy Upgrades $19 → $26 | Hold → Buy | Upgrades | $19 → $26 | +17.28% | Nov 5, 2025 |
Financial Forecast
Revenue This Year
2.17B
from 1.90B
Increased by 13.83%
Revenue Next Year
1.61B
from 2.17B
Decreased by -25.82%
EPS This Year
-5.41
from 2.34
EPS Next Year
2.62
from -5.41
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 2.3B | 2.3B | ||||
| Avg | 2.2B | 1.6B | ||||
| Low | 2.0B | 1.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 19.5% | 8.4% | ||||
| Avg | 13.8% | -25.8% | ||||
| Low | 7.4% | -40.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -2.16 | 6.06 | ||||
| Avg | -5.41 | 2.62 | ||||
| Low | -6.53 | 0.10 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.